08 · Strategy
Sequencing, positioning, and the moat.
The Market tab argued where the wedge is. This tab argues how we close it: positioning canvas, four-quadrant Pareto segmentation, three-tier bolt-on pricing, the cannibalization talk track BD needs internally, five battle cards, and the four-layer compound moat.
Positioning canvas
One sentence, six clauses.
- For
- Brand Insights Directors at Top-20 pharma already buying ZoomRx trackers
- Who need
- continuous HCP signal between quarterly tracker waves - without re-cycling procurement or stealing budget from existing studies
- Sagan is
- Sagan - AI-moderated async HCP listening as a bolt-on to existing tracker contracts
- That delivers
- weekly digest of physician sentiment, competitive perception, and prescribing-driver shifts, synthesized into a live dashboard, not a quarterly deck
- Unlike
- Outset / Strella / Listen Labs (no pharma panel, no tracker integration, second-vendor risk) and Kantar / IQVIA / Trinity (quarterly cadence, 8-week study cycles, deck-only deliverables)
- Sagan uniquely offers
- the only stack with verified pharma panel × therapeutic-area spine × Sagan Agents × existing MSA - and we already sit inside your tracker contract
Messaging house
Three pillars. One umbrella.
Umbrella message
The only AI moderator already inside your tracker contract.
01 · Expansion, not replacement
We add a new line item. We don't displace your IDIs.
AI qual covers use cases traditional methods can't reach at this cost - continuous, async, light-touch HCP listening. IDIs and focus groups stay where they're best: depth on N=10. Sagan covers continuous breadth on N=50-100.
02 · Bolt-on, not new procurement
Sits inside your existing tracker contract.
MSA already signed. Vendor master record already in place. 21CFR/HIPAA posture already cleared. The bolt-on quote sits at 25-35% of tracker TCV - no new vendor onboarding cycle.
03 · Pharma-grade, not Mechanical Turk
Same panel, same compliance, same therapeutic depth.
60,000+ verified HCPs (ISO 20252-grade). Pre-built discussion guides per therapeutic area with branch logic. 24-hour PV / AE workflow backed by an in-session EphMRA 4-criteria listener (live in the demo moderator). Probe rate ≥0.6, depth ≥3.5, JSON-schema synthesis with 0 off-guide brand names - all computed per transcript, not asserted.
Account segmentation
Pareto-cut the book. Sequence the quadrants.
Anchor pitch · PM-led
Goal: multi-brand framework $500K-1M+ · sets pricing benchmark
Warm intro only · pitch Year 2
Goal: build relationship · don't pitch product yet
Avoid · address relationship
Don't pitch. Relationship repair first.
Validation pitches · BD-led
Goal: 2-3 paid pilots at half-rate · first lighthouse logo
Volume conversion · BD-led
Goal: bulk of Year-1 revenue · expand on lighthouse case
Feedback pitches · BD + PM
Goal: harvest objections · conversion is secondary
Sequencing logic - validate with strong-bond long-tail first, harden against tough clients second, anchor at whales third.
- Q4 (long-tail × strong bond): pitch first, Days 30-45. Goal: 2-3 paid pilots at half-rate. These are validation conversions.
- Q5 (long-tail × medium bond): bulk of Year-1 volume. Pitch Days 45-60+ after Q4 lighthouse lands.
- Q6 (long-tail × poor bond): feedback pitches Days 45-60. Frame as 'help us pressure-test this before senior buyers.' Conversion secondary, objection harvest primary.
- Q1 (whale × strong bond): warm intros Day 60+, anchor pitch Days 75-90. PM-led, not BD-led. Goal: multi-brand framework at $500K-1M+.
- Q2 (whale × medium bond): warm intros Day 75+, pitch lands Year 2.
- Q3 (whale × poor bond): not Year 1. Address the relationship issue separately.
Pricing & packaging
Pilot. Bolt-on. Anchor framework.
Land
Pilot
$50-70K
90-day pilot · single brand
Half-rate bolt-on. Single brand team. One success criterion.
- Continuous async listening · 50-100 HCP conversations over 90 days
- Weekly digest agent + live dashboard
- Under existing tracker MSA · no new procurement gate
- Quality SLA: probe rate ≥0.6, depth ≥3.5, drop-off <8%
- PM joins every external call in the first 10
Target buyer
Brand Insights Director (existing tracker buyer)
Close weapon
Live demo of /sagan/moderator + half-rate offer
Expand
Production unitBolt-on
$100-140K /yr
Annual · committed capacity per brand
Production bolt-on at 25-35% of existing tracker TCV.
- Committed capacity (e.g., 100 interviews/yr or 4 listening waves between trackers)
- Sagan Agents stack: weekly digest, competitive watch, archetype shift detector
- Quarterly business review + therapeutic-area SME hour
- Renewal locked into annual research plan (Sept-Nov)
Target buyer
Brand Insights Director + TA Insights Lead
Close weapon
Pilot lighthouse case study + tracker-renewal alignment
Anchor
Multi-brand framework
$500K-1M+ /yr
Multi-year · franchise-wide
Anchor pricing. Locks competitors out of the franchise.
- Unlimited Sagan use across N brand teams in a franchise
- Co-developed agent roadmap · joint QBR
- Volume pricing: $40K/study marginal cost at scale
- Preferred-methodology-vendor status
Target buyer
VP / Head of Insights
Close weapon
Reference call with first multi-brand customer + competitive lockout pitch
Why bolt-on, not standalone
The bolt-on price sits inside an existing tracker contract under an existing MSA. That structure removes three otherwise-fatal frictions: (i) no new procurement cycle (saves 4-8 weeks), (ii) no new MSA (saves 3-9 months), (iii) Sagan reads as “more ZoomRx” rather than “new vendor” - the buyer's default-yes posture stays intact. Standalone pricing comes only at the multi-brand framework tier where the customer has actively chosen Sagan as the platform.
Cannibalization positioning · internal-only
BD won't pitch what threatens their own book.
The single most important positioning move sits inside the company, not in front of clients. If BD sees Sagan as competing with their IDI quota, no amount of external messaging will save the GTM. This is the talk track every BD must internalize before the first external pitch.
What BD hears first
“Sagan replaces our IDI work. Every Sagan deal I sell is a tracker hour I lose.”
Why that's wrong
AI qual covers continuous, async, light-touch HCP listening - a use case IDIs and focus groups physically cannot serve at this cost and cadence. It is genuinely new spend.
Internal talk track (verbatim)
AI qual extends our methodology stack. It does not replace IDIs or focus groups; it covers the use cases those methods cannot serve well. We are bringing AI qual to our clients because if we do not, AI-native MR entrants will - and they will become the second vendor in our accounts.
What success looks like
BD quotes Sagan unprompted in tracker-renewal conversations. Sagan ACV growth inside an account exceeds tracker ACV growth in the same account (expansion ratio >1.0).
Battle cards
What they say. What we say back.
VS. Outset (outset.ai)
Their angle
“We’re AI-native, HIPAA-compliant, $51M raised ($30M Series B, Dec 2025), 8x growth in 2025. We’ll bring AI moderation to your team.”
Our return
We have all that, plus the panel you already pay us for, the tracker you already buy, and the MSA you signed three years ago. They’re landing as a second vendor in our account - we’d rather we be the first.
VS. Listen Labs
Their angle
“$69M Series B (Jan 2026, $100M total raised), 1M+ interviews, viral marketing. We scale.”
Our return
Volume isn’t depth. 1M consumer interviews don’t survive a brand-team scrutiny on adverse-event flagging. We probe to 0.6+ rate with a verified HCP panel and a 24-hour PV workflow. They’re brand-unsafe for pharma.
VS. Kantar / Oracle Cerner Enviza
Their angle
“We’ve done your last 30 studies. We have the relationship.”
Our return
And it cost $200K and 8 weeks per wave. Sagan ships the same n=12 oncology read for $50-70K in 12 weeks of continuous listening - and we hand it to you as a dashboard, not a deck. Your relationship with us isn’t at risk; we’re still ZoomRx.
VS. M3 / Sago panel-only
Their angle
“We have the panel. You can’t do qual without us.”
Our return
Sagan’s 60,000-HCP panel covers oncology, immunology, rare disease at comparable depth - and we wrap it in a moderator + agents they don’t have. Net better unit economics, and we already run inside the client’s tracker.
VS. Trinity Life Sciences
Their angle
“Senior-led strategy. We told you Tagrisso would win. Pay us $400K.”
Our return
We give you Tagrisso’s prescriber sentiment continuously, not in a deck six months after the fact. Trinity does strategy. Sagan is the qual rail Trinity needs. Year-2 co-sell candidate, not Year-1 competitor.
The compound moat
Four layers. All four, all the time.
01 · Verified pharma HCP panel
60,000+ HCPs · ISO 20252-grade · 19 of 20 top pharma trust the recruit
Time to replicate
24-36 months
Horizontal blind spot
Outset, Strella, Listen Labs have zero pharma-specific panel
02 · Therapeutic-area discussion-guide library
Pre-built guides + must-capture data points across 8+ indications, branch logic per disease
Time to replicate
12-18 months · requires therapeutic-area SMEs + KOL validation
Horizontal blind spot
Horizontal AI has generic templates · no oncology-grade probe libraries
03 · Tracker-contract embed
ZoomRx MSAs at 19 of 20 top pharma · existing trackers · existing buyer relationships
Time to replicate
12-24 months for a new vendor · cold-to-PVL is the slowest gate
Horizontal blind spot
Kantar/IQVIA have the MSA but lack AI · Outset/Strella have AI but no MSA
04 · Sagan Agents orchestration
AI OS for insights workflows · launched 2026-05-20 · category-defining first mover
Time to replicate
18-36 months · agent platform + brand-team integrations + governance
Horizontal blind spot
Listen Labs closest on scale, no agent layer, no pharma posture
Compound moat: any single layer is replicable. The product is the stack - panel × therapeutic spine × tracker embed × agents. A new entrant must rebuild all four sequentially because each unlocks the next. The Sagan Agents announcement (2026-05-20) is the first time all four sit in one product.
Provenance: panel scale (60,000+ HCPs, 30+ specialties) and coverage (19 of the top 20 global pharma) are ZoomRx public disclosures. ISO 26362 was withdrawn and folded into ISO 20252:2019, so the panel standard is cited as ISO 20252. Pricing, quadrant sequencing and competitor raise figures are illustrative unless separately cited.